CAMK2G and neoplasm: Here we show by luminescence imaging that the inhibition of VEGFRs by CBO-P11 or CaMKII by KN-93 reduces tumor burden by 44% and 52%, respectively, while the combined treatment with both KN-93 and CBO-P11 resulted in even greater reductions in tumor size (74%) when compared to that of the saline treated control group (Fig 7A and 7B).